EMAIL THIS PAGE TO A FRIEND

Malaria journal

Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates.


PMID 24916383

Abstract

Spreading resistance of Plasmodium falciparum to existing drugs calls for the search for novel anti-malarial drugs and combinations for the treatment of falciparum malaria. In vitro and ex vivo investigations were conducted with fresh P. falciparum field isolates and culture-adapted P. falciparum clones to evaluate the anti-malarial potential of mirincamycin, a lincosamide, alone and in combination with tafenoquine (TQ), dihydroartemisinin (DHA), and chloroquine (CQ). All samples were tested in a histidine-rich protein 2 (HRP2) drug susceptibility assay. Interaction analysis showed additive to synergistic interaction profiles with these potential partner drugs, with an overall geometric mean fractional inhibitory concentration at 50% inhibition (FIC₅₀) of 0.78, 0.80 and 0.80 for mirincamycin with TQ, DHA, and CQ, respectively. Antagonism was not found in any of the tested field isolates or clones. The strongest tendency toward synergy (i.e. the lowest FIC) was seen with a combination ratio of 1:0.27 to 1:7.2 (mean 1:2.7) for the combination with tafenoquine. The optimal combination ratios for DHA and CQ were 1:444.4 to 1:36,000 (mean 1:10,755.5) and 1:2.7 to 1:216 (mean 1:64.5), respectively. No evidence of an activity correlation (i.e. potential cross-resistance) with DHA, mefloquine, quinine or chloroquine was seen whereas a significant correlation with the activity of clindamycin and azithromycin was detected. Mirincamycin combinations may be promising candidates for further clinical investigations in the therapy and prophylaxis of multidrug-resistant falciparum malaria or in combination with 4 or 8-aminoquinolines for the treatment and relapse prevention of vivax malaria.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

75199
Azithromycin, analytical standard
C38H72N2O12
1046056
Azithromycin, United States Pharmacopeia (USP) Reference Standard
C38H72N2O12 · 2H2O
Y0000306
Azithromycin, European Pharmacopoeia (EP) Reference Standard
C38H72N2O12 · 2H2O
Y0000637
Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
C38H72N2O12 · 2H2O
Y0000641
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
C38H72N2O12 · 2H2O
1046067
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
C38H72N2O12
1136002 Clindamycin hydrochloride, United States Pharmacopeia (USP) Reference Standard
C18H33ClN2O5S · HCl · H2O
C5269
Clindamycin hydrochloride, lincosamide antibiotic
C18H33ClN2O5S · HCl
PHR1159 Clindamycin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
C18H33ClN2O5S · HCl · H2O
C2250000
Clindamycin hydrochloride, European Pharmacopoeia (EP) Reference Standard
C18H33ClN2O5S · HCl
D7439
Dihydroartemisinin, analytical standard, mixture of α and β isomers
C15H24O5
M2319
Mefloquine hydrochloride, ≥98% (HPLC), powder
C17H17ClF6N2O
M0253000
Mefloquine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C17H17ClF6N2O
22620
Quinine, suitable for fluorescence, anhydrous, ≥98.0% (dried material, NT)
C20H24N2O2
145904
Quinine, 90%
C20H24N2O2
69311
Quinine, certified reference material, TraceCERT®
C20H24N2O2